[医药制造业] [2023-11-06]
医药生物板块,2023 年 Q1-Q3 上市公司收入增速同比下降 6.44pct,归母净利润增速同比下降 20.47pct。2023Q1-Q3 医药生物板块上市公司营业收入同比增长 2.90%,其中单 Q3 营业收入同比减少 2.72%,受到医药政策影响,医药板块收入短期承压。利润端来看,2023Q1-Q3 医药生物板块上市公司归母净利润同比减少 12.98%,其中单 Q3 归母净利润减少 11.24%。
[医药制造业] [2023-11-03]
糖尿病与体重管理药物市场需求广阔,GLP-1受体激动剂由于能促进胰岛素分泌并降低食欲控制体重,而且不容易引发低血糖等副作用,因此市场需求不断扩大。司美格鲁肽在降糖与减重方面效果较好,而且在慢性肾病、心血管病、非酒精性脂肪肝炎(Nash)等方面临床表现均较好,预计需求将继续增加。
[医药制造业] [2023-11-02]
全球痴呆患者超5500万,阿尔兹海默病占比约60%-70%。根据WHO报道,目前全球痴呆症患者已超5500万,其中阿尔兹海默病患者的占比约60%-70%,对应人群在3300-3850万。随着阿尔兹海默病患者的疾病进展,患者将逐步失去独立生活能力,不仅影响患者的生活质量,而且对病患的护理人员、家人和整个社会都有身体、心理、社会和经济影响。
[医药制造业] [2023-11-01]
体外诊断是指将血液、体液、组织等样本从人体中取出,使用体外检测试剂、 仪器等对样本进行检测与校验,以便对疾病进行预防、诊断、治疗检测、后 期观察、健康评价、遗传疾病预测。体外诊断产品主要由诊断设备(仪器) 和诊断试剂构成,根据检测原理方法以及检测环境条件可以分成包括生化诊 断、免疫诊断、分子诊断、现场即时检测(POCT)等主要领域。
[化学原料和化学制品制造业,医药制造业] [2023-11-01]
Sexual Lubricants, also known as lubes or personal lubricants, are a kind of gel, cream, fluid, or liquid that are used to reduce friction between the vagina & penis during sexual intercourse and reduces pain. Lubes are used to enhance the sexual experience and get more pleasure. Using sexual lubricants while sexual intercourse may be helpful for women experiencing vaginal dryness, & men who have erectile dysfunction. These are used widely for men, women, transgender, and LGBTQ+ community globally. They are used with condoms as well for additional comfort & ease and sometimes to reduce condom breakage. These lubricants are applied to the condom, penis, vagina, or rectum during sexual activity as it improves moistening. They are generally preferred by sex workers and men who have sex with men (MSM).
[医药制造业] [2023-11-01]
Sexual health supplements help improve potency during sexual activities, erectile dysfunction, infertility, and other conditions. They are consumed orally. Sexual health supplements are available in the market without a prescription and usually do not have any side effects on the human body. They are available in capsules, tablets, soft gels, liquids, and powders. Nutritional supplements are a part of the daily diet globally due to aging, lifestyle changes, and other factors. Common supplements include minerals, vitamins, and herbal products.
[医药制造业] [2023-11-01]
Self/home-based pregnancy test kits were the first rapid test kits under point-of-care (POC) diagnostics developed in 1976. The pregnancy test kit was developed in 1976. Pregnancy test kits are medical devices used to detect signs of pregnancy among women. The Human Chorionic Gonadotropin (hCG) hormone is considered a standard gold biomarker that provides overall information about pregnancy to identify the pregnancy. This hormone develops in the placenta during pregnancy. It helps to thicken the uterine lining, which supports to growth embryo and sends the signal to the body to stop menstruation. The level of hCG increase after conception and continue to increase until around ten weeks into pregnancy.
[医药制造业,信息传输、软件和信息技术服务业] [2023-11-01]
Infection control surveillance solutions are an integral component of healthcare systems that are designed to help prevent and control HAIs. These solutions range from comprehensive infection control systems that incorporate surveillance of pathogens, antimicrobial therapy management, infection prevention strategies, and antibiotic stewardship programs to more focused solutions that help track and monitor nosocomial and antimicrobial resistance (AMR) in a hospital setting. By recognizing the scope and prevalence of HAIs, infection control surveillance solutions help health professionals identify areas of potential concern and reduce the impact of infectious outbreaks.
[医药制造业] [2023-10-31]
国内二类苗市场快速发展,重磅产品有望持续放量。近年来,全球疫苗市场呈现快速发展,驱动因素主要是由发达国家及发展中国家创新疫苗的普及、不断增长的医疗支出及疫苗接种意识的提高。新冠疫苗研发也推动了疫苗相关技术的进一步发展。国内疫苗市场也处于加速发展中,增速快于全球市场。且随着人均可支配收入提升,以及人群预防接种意识的觉醒和新品种诱发的接种需求,预计二类苗产品的市场规模将持续扩大。随着国产重磅疫苗产品陆续上市并实现国产替代,国内疫苗行业进入大品种时代,国内婴幼儿及成人重磅疫苗产品有望持续放量,渗透率提升空间较大。
[医药制造业] [2023-10-31]
诺和诺德司美格鲁肽在此前CVOT 临床试验成功的基础上又再下一城,在 慢性肾病FLOW III 期临床研究中因达到预期终点而提前终止临床试验,相 应用药人群全球超1 亿人,市场空间超200 亿美元。我们认为,GLP-1 类 药物目前已在2 型糖尿病、超重与肥胖、心脑血管疾病、射血分数保留型 心衰和慢性肾病中展现出临床获益,可覆盖人群庞大。未来,GLP-1 类药 物有望在NASH 和AD 等适应症中迎来突破,造福更多患者的同时进一步 提升靶点及产业价值。